Lineage Cell Therapeutics Launches New Corneal Endothelial Cell Therapy COR1
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2026
0mins
Should l Buy LCTX?
Lineage Cell Therapeuticy announced the expansion of its cell transplant pipeline with the launch of COR1, a new corneal endothelial cell therapy program, in preclinical development for the treatment of corneal endothelial disease. Corneal endothelial disease is a progressive, often hereditary condition where cells on the inner layer of the cornea die, causing cornea swelling and vision loss. Applicable indications for COR1 are expected to include Fuchs Endothelial Corneal Dystrophy and Bullous Keratopathy. Utilizing Lineage's proprietary cell manufacturing and expansion platform, AlloSCOPE, the Company has manufactured "off the shelf" corneal endothelial cells with identity, morphological, and functional characteristics which meet initial internal criteria and support further development. Lineage plans to advance this new product candidate into preclinical testing and will provide additional developmental updates on the COR1 program as they become available. "Corneal endothelial disease is natural next application of our platform. Millions of people are candidates for corneal transplants for which today there is only one donor for every 70 diseased eyes globally. The current supply of CEnC's from cadaveric sources is further limited by the low availability of organ donors, as well as by inconsistent yield and quality. We believe we are well positioned to produce and provide a consistent and "off-the-shelf" allogeneic source of CEnC's by applying our proprietary AlloSCOPE platform and our development expertise from the OpRegen program to this new ophthalmology program," stated Brian Culley, CEO. "Importantly, CEnC therapy from cadaveric sources has already been approved in Japan to treat corneal endothelial disease, providing evidence for the underlying mechanism of action. Having this clinical and regulatory precedent creates a highly attractive opportunity for us to develop a more consistent and cost-effective product that could address the global shortage of donor cells. We have leveraged the capabilities of our AlloSCOPE platform and a proprietary pluripotent cell line to launch this new, internally-developed and wholly-owned initiative, and have successfully manufactured and characterized corneal endothelial cells that meet our initial attributes for identity and scale. We have elected to advance the COR1 program into preclinical testing and we also believe the recent accomplishments reported with our AlloSCOPE "5D" manufacturing process could be applied to this program to further reduce production costs through large-scale production."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LCTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LCTX
Wall Street analysts forecast LCTX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.710
Low
3.00
Averages
4.50
High
9.00
Current: 1.710
Low
3.00
Averages
4.50
High
9.00
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avaí Bio and Austrianova Advance Anti-Aging Therapy Collaboration
- Anti-Aging Therapy Progress: Avaí Bio and Austrianova's joint venture Klothonova will present the latest data on their α-Klotho anti-aging therapy at the September 2026 Klotho Conference, marking the company's ongoing innovation and leadership in the anti-aging sector.
- Significant Market Potential: The global longevity biotech market is projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034, representing a compound annual growth rate of 12.84%, highlighting the vast opportunities for cellular therapies and gene editing technologies.
- Technological Platform Advantage: Klothonova employs the Cell-in-a-Box® technology to protect genetically modified cells, ensuring they continuously produce α-Klotho protein in the body, thus providing a sustainable solution for anti-aging treatments and enhancing market competitiveness.
- Diverse Product Line: In addition to the α-Klotho program, Avaí Bio's Insulinova project targets diabetes, directly overlapping with one of the fastest-growing therapeutic segments in anti-aging medicine, further solidifying the company's market position.
See More
Cell Therapy Market Set to Nearly Double by 2035
- Market Growth Potential: The global cell therapy manufacturing market is projected to grow from $7.17 billion in 2026 to over $14 billion by 2035, with a compound annual growth rate of 15.2%, indicating strong demand and investment appeal in this sector.
- FDA Policy Advancement: In early 2026, the FDA formalized flexible manufacturing and quality control oversight, clearing the path for the transition from clinical validation to commercial products, thus accelerating industry growth and innovation.
- Avaí Bio's Progress: Avaí Bio, in partnership with Austrianova, has commenced the production of a Master Cell Bank (MCB) for α-Klotho protein, establishing a foundational infrastructure that ensures compliance with the highest quality standards for future cell therapy products.
- Technological Innovation and Market Demand: Avaí Bio's Cell-in-a-Box® encapsulation platform will utilize cells from the MCB to create a therapy that continuously produces Klotho protein, addressing the growing demand for anti-aging treatments and holding significant market potential.
See More
Avaí Bio Initiates Production of α-Klotho Cells
- Production Milestone: Avaí Bio has initiated the manufacturing of a Master Cell Bank for α-Klotho protein in collaboration with Austrianova, marking a significant transition from laboratory theory to production reality, which is expected to enhance the market potential for anti-aging therapies.
- Broad Market Outlook: The global cell therapy market surpassed $8.2 billion in 2026 and is projected to exceed $45 billion by 2035, positioning Avaí Bio's technology to capture a significant share in this rapidly growing sector.
- Technological Innovation: The Cell-in-a-Box® technology protects transplanted cells from immune system attacks, allowing them to continuously produce α-Klotho, addressing a critical challenge in cell therapy and enhancing treatment efficacy and safety.
- Dual-Program Strategy: Avaí Bio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program, targeting enormous markets such as Alzheimer's disease, cardiovascular diseases, and kidney disease, demonstrating its strategic positioning in the biotechnology field.
See More
Avaí Bio Initiates α-Klotho Cell Production
- Manufacturing Milestone: Avaí Bio has initiated the production of a Master Cell Bank for α-Klotho protein in collaboration with Austrianova, marking a significant transition from laboratory theory to production reality, which is expected to accelerate the commercialization of anti-aging therapies.
- Massive Market Potential: The global cell therapy market surpassed $8.2 billion in 2026 and is projected to exceed $45 billion by 2035, positioning Avaí Bio's technology to capture a significant share in this rapidly growing sector.
- Technological Advantage: The Cell-in-a-Box® technology protects therapeutic cells from immune system attacks, allowing them to continuously produce α-Klotho, addressing the low survival rates of transplanted cells and enhancing the sustainability of treatment outcomes.
- Strategic Positioning: Avaí Bio's dual-program approach targets both the Klothonova anti-aging platform and the Insulinova diabetes program, with enormous addressable markets, as the Alzheimer's disease market alone is projected to reach $32.8 billion by 2033.
See More
Major Wall Street Rating Changes on Wednesday
- Starbucks Downgrade: RBC downgraded Starbucks from Outperform to Sector Perform, citing a slower-than-expected turnaround in the U.S. business, which has not yielded the anticipated small investments, making it difficult to justify an Outperform rating and negatively impacting stock performance.
- NRG Energy Upgrade: Wolfe upgraded NRG Energy from Peer Perform to Outperform, highlighting its strong positioning as a data center beneficiary with over 6 GW of gas new build potential, which enhances the company's diversification and long-term power generation capabilities.
- Block Stock Outlook: Truist upgraded Block from Hold to Buy, noting that after a ~40% reduction in workforce, the stock has significantly de-rated, and improving free cash flow could lead to unexpected capital returns, boosting market confidence.
- Netflix Reinstatement: Citi reinstated Netflix as Buy, forecasting an increase in FY26 EBIT guidance and a U.S. price hike in Q4 2026, with these catalysts expected to drive a stock price increase of 5% to 17%.
See More
Lineage Cell Therapeutics Q4 2025 Earnings Call Insights
- Extended Cash Runway: Lineage has extended its cash runway to Q2 2028 through recent warrant exercises, which is expected to support planned operations and reflects positive progress in financial management.
- Clinical Research Expansion: The GAlette study has added 10 new clinical sites, significantly up from 8 in the previous 6 months, indicating the company's proactive stance in clinical trial preparations that could facilitate later-stage trials.
- Revenue Growth: Total revenues for Q4 2025 reached $6.6 million, an increase of $3.7 million compared to Q4 2024, primarily driven by higher collaboration revenue from the Roche agreement, showcasing success in partnership development.
- Increased R&D Spending: R&D expenses for the fourth quarter totaled $8.2 million, up $4.8 million year-over-year, demonstrating the company's ongoing investment in technology development, despite an overall net loss of $63.5 million largely due to non-cash charges.
See More
Avaí Bio and Austrianova Advance Anti-Aging Therapy Collaboration
- Anti-Aging Therapy Progress: Avaí Bio and Austrianova's joint venture Klothonova will present the latest data on their α-Klotho anti-aging therapy at the September 2026 Klotho Conference, marking the company's ongoing innovation and leadership in the anti-aging sector.
- Significant Market Potential: The global longevity biotech market is projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034, representing a compound annual growth rate of 12.84%, highlighting the vast opportunities for cellular therapies and gene editing technologies.
- Technological Platform Advantage: Klothonova employs the Cell-in-a-Box® technology to protect genetically modified cells, ensuring they continuously produce α-Klotho protein in the body, thus providing a sustainable solution for anti-aging treatments and enhancing market competitiveness.
- Diverse Product Line: In addition to the α-Klotho program, Avaí Bio's Insulinova project targets diabetes, directly overlapping with one of the fastest-growing therapeutic segments in anti-aging medicine, further solidifying the company's market position.
See More
Cell Therapy Market Set to Nearly Double by 2035
- Market Growth Potential: The global cell therapy manufacturing market is projected to grow from $7.17 billion in 2026 to over $14 billion by 2035, with a compound annual growth rate of 15.2%, indicating strong demand and investment appeal in this sector.
- FDA Policy Advancement: In early 2026, the FDA formalized flexible manufacturing and quality control oversight, clearing the path for the transition from clinical validation to commercial products, thus accelerating industry growth and innovation.
- Avaí Bio's Progress: Avaí Bio, in partnership with Austrianova, has commenced the production of a Master Cell Bank (MCB) for α-Klotho protein, establishing a foundational infrastructure that ensures compliance with the highest quality standards for future cell therapy products.
- Technological Innovation and Market Demand: Avaí Bio's Cell-in-a-Box® encapsulation platform will utilize cells from the MCB to create a therapy that continuously produces Klotho protein, addressing the growing demand for anti-aging treatments and holding significant market potential.
See More
Avaí Bio Initiates Production of α-Klotho Cells
- Production Milestone: Avaí Bio has initiated the manufacturing of a Master Cell Bank for α-Klotho protein in collaboration with Austrianova, marking a significant transition from laboratory theory to production reality, which is expected to enhance the market potential for anti-aging therapies.
- Broad Market Outlook: The global cell therapy market surpassed $8.2 billion in 2026 and is projected to exceed $45 billion by 2035, positioning Avaí Bio's technology to capture a significant share in this rapidly growing sector.
- Technological Innovation: The Cell-in-a-Box® technology protects transplanted cells from immune system attacks, allowing them to continuously produce α-Klotho, addressing a critical challenge in cell therapy and enhancing treatment efficacy and safety.
- Dual-Program Strategy: Avaí Bio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program, targeting enormous markets such as Alzheimer's disease, cardiovascular diseases, and kidney disease, demonstrating its strategic positioning in the biotechnology field.
See More
Avaí Bio Initiates α-Klotho Cell Production
- Manufacturing Milestone: Avaí Bio has initiated the production of a Master Cell Bank for α-Klotho protein in collaboration with Austrianova, marking a significant transition from laboratory theory to production reality, which is expected to accelerate the commercialization of anti-aging therapies.
- Massive Market Potential: The global cell therapy market surpassed $8.2 billion in 2026 and is projected to exceed $45 billion by 2035, positioning Avaí Bio's technology to capture a significant share in this rapidly growing sector.
- Technological Advantage: The Cell-in-a-Box® technology protects therapeutic cells from immune system attacks, allowing them to continuously produce α-Klotho, addressing the low survival rates of transplanted cells and enhancing the sustainability of treatment outcomes.
- Strategic Positioning: Avaí Bio's dual-program approach targets both the Klothonova anti-aging platform and the Insulinova diabetes program, with enormous addressable markets, as the Alzheimer's disease market alone is projected to reach $32.8 billion by 2033.
See More
Major Wall Street Rating Changes on Wednesday
- Starbucks Downgrade: RBC downgraded Starbucks from Outperform to Sector Perform, citing a slower-than-expected turnaround in the U.S. business, which has not yielded the anticipated small investments, making it difficult to justify an Outperform rating and negatively impacting stock performance.
- NRG Energy Upgrade: Wolfe upgraded NRG Energy from Peer Perform to Outperform, highlighting its strong positioning as a data center beneficiary with over 6 GW of gas new build potential, which enhances the company's diversification and long-term power generation capabilities.
- Block Stock Outlook: Truist upgraded Block from Hold to Buy, noting that after a ~40% reduction in workforce, the stock has significantly de-rated, and improving free cash flow could lead to unexpected capital returns, boosting market confidence.
- Netflix Reinstatement: Citi reinstated Netflix as Buy, forecasting an increase in FY26 EBIT guidance and a U.S. price hike in Q4 2026, with these catalysts expected to drive a stock price increase of 5% to 17%.
See More
Lineage Cell Therapeutics Q4 2025 Earnings Call Insights
- Extended Cash Runway: Lineage has extended its cash runway to Q2 2028 through recent warrant exercises, which is expected to support planned operations and reflects positive progress in financial management.
- Clinical Research Expansion: The GAlette study has added 10 new clinical sites, significantly up from 8 in the previous 6 months, indicating the company's proactive stance in clinical trial preparations that could facilitate later-stage trials.
- Revenue Growth: Total revenues for Q4 2025 reached $6.6 million, an increase of $3.7 million compared to Q4 2024, primarily driven by higher collaboration revenue from the Roche agreement, showcasing success in partnership development.
- Increased R&D Spending: R&D expenses for the fourth quarter totaled $8.2 million, up $4.8 million year-over-year, demonstrating the company's ongoing investment in technology development, despite an overall net loss of $63.5 million largely due to non-cash charges.
See More
